Skip to Content
Merck
  • Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.

Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.

Clinical cancer research : an official journal of the American Association for Cancer Research (2011-03-10)
Tetsuji Takayama, Hiroyuki Nagashima, Masahiro Maeda, Shuichi Nojiri, Michiaki Hirayama, Yoichiro Nakano, Yasuo Takahashi, Yasushi Sato, Hitoshi Sekikawa, Mitsuru Mori, Tomoko Sonoda, Tetsuo Kimura, Junji Kato, Yoshiro Niitsu
ABSTRACT

On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of colorectal cancer. Randomly assigned to sulindac (300 mg daily), etodolac (400 mg daily), and placebo groups were 189 subjects without polyps or who had undergone polypectomy. Drugs were administered for 2 months. ACF in the rectal region were counted by magnifying endoscopy. Occurrence of polyps was evaluated at 12 months. A planned interim analysis was conducted. ACF number at 2 months was significantly suppressed in the sulindac group (P = 0.0075), but not in the etodolac group (P = 0.73). In the sulindac group, the numbers of adenomas plus hyperplastic polyps (total polyps) and adenomas at 12 months were significantly (P = 0.02) and marginally (P = 0.064) lower, respectively, in comparison with the placebo group; no such difference was observed in the etodolac group. In analysis of only polypectomized subjects, the numbers of total polyps and adenomas in the sulindac group were even more markedly lower, with P values of 0.014 and 0.034, respectively. A similar tendency was confirmed by analyses of the incidence of polyps at 12 months. Suppression rates of total polyps and adenomas in ACF responders to sulindac were significantly greater than in nonresponders. In all groups, compliance was more than 90% and no intolerable adverse effects were observed. ACF may be useful as surrogate lesions for chemoprevention of colorectal cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Etodolac
SKU
Pack Size
Availability
Price
Quantity
Etodolac, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity